Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide

Annals of the Rheumatic Diseases

Volumn 55, Issue 4, 1996, Pages 224-229

  McDermott, Elizabeth M ^a   Powell, Richard J ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ADULT; AMENORRHEA; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MENSTRUATION; NEUTROPHIL; OVARY INSUFFICIENCY; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0029968720     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.55.4.224     Document Type: Article

References (39)

1. Wang C L, Wang F, Bosco J J. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995; 4: 11-4.
2. Boumpas D T, Austin H A, Vaughn E M, Yarboro C H, Klippel J H, Balow J E. Risk for sustained amenorrhoea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intent Med 1993; 119: 366-9.
3. Chapman R M, Sutcliffe S B, Malpass J S. Cytotoxic-induced ovarian failure in women with Hodgkin's disease. JAMA 1979; 242: 1171-81.
4. Warne G L, Fairley K F, Hobbs J B, Martin F I R. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973; 289: 1159-62.
5. Austin H A, Klippel J H, Balow J E, et al. Therapy of lupus nephritis. Controlled trial of prednisolone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9.
6. Sanders J E, Buckner C D, Amos D, et al. Ovarian function following marrow transplantation for aplastic anaemia or leukaemia. J Clin Oncol 1988; 6: 813-8.
7. Belmont H M, Storch M, Buyon J, Abramson S. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 1995; 4: 104-8.
8. Langevitz P, Klein L, Pras M, Many A. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 1992; 28: 157-8.
9. Uldall P R, Kerr D N S, Tacchi D. Sterility and cyclophosphamide. Lancet 1972; 1: 693-4.
10. Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977; 39: 1403-9.
11. Steinberg A D, Decker J L. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum 1974; 17: 923-37.
12. Decker J L, Klippel J H, Plotz P H, Steinberg A D. Cyclophosphamide or azathioprine in lupus glomerulonephritis: a controlled trial: results at 28 months. Ann Intern Med 1975; 83: 606-15.
13. Luqmani R A, Palmer R G, Bacon P A. Azathioprine, Cyclophosphamide and chlorambucil. Bailliere's Clin Rheumatol 1990; 4: 595-619.
14. Clayton P E, Shalet S M, Price D A. Gonadal function after chemotherapy and irradiation for childhood malignancies. Horm Res 1988; 30: 104-10.
15. Fox D A, McCune W J. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 1994; 20: 265-99.
16. Roubenoff R, Hoyt J, Petri M, Hochberg M C, Hellmann D B. Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 1988; 18: 88-110.
17. Chapman R M, Sutcliffe S B. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 1981; 58: 849-51.
18. Tan E M, Cohen A S, Fries J F, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
19. Mattison D. Effects of smoking on fertility from gametogenesis to implantation. Environ Res 1982; 28: 410-33.
20. Brambilla D J, McKinlay S M. A prospective study of factors affecting age at menopause. J Clin Epidemiol 1989; 42: 1031-9.
21. Stanford J L, Hartge P, Brinton L A, Hoover R N, Brookmeyer R. Factors influencing the age at natural menopause. J Chron Dis 1987; 40: 995-1002.
22. Whelan E A, Sandler D P, McConnaughey D R, Weinberg C R. Menstrual and reproductive characteristics and age at natural menopause. Am J Epidemiol 1990; 131: 625-32.
23. Richardson S J. The biological basis of the menopause. Balliere's Clin Endocrinol Metab 1993; 7: 1-16.
24. Symonds E M, ed. The changes of the menstrual cycle. In: Essential obstetrics and gynaecology, 2nd edn, chapter 21. Edinburgh: Churchill Livingstone, 1992, 209-17.
25. Anderson M, Braude P, Cardoza L, et al. Contraception and sterilization. In: Chamberlain G V P, ed. Gynaecology by Ten Teachers, 14th edn, chapter 11, part iii. London: Edward Arnold, 1986; 242-3.
26. Metcalfe M G. The approach of menopause: a New Zealand study. N Z Med J 1988; 101: 103-6.
27. Genuth S M. The reproductive glands. In: Berne R M, Levy M N, eds. Physiology, chapter 51. Missouri: Mosby Year Book, 1993; 1006-7.
28. Ataka K, Moohissi K. Chemotherapy induced premature ovarian failure: mechanisms and prevention. Steroids 1989; 54: 607-26.
29. Clements P J, Davies J. Cytotoxic drugs: their clinical application to the rheumatic diseases. Semin Arthritis Rheum 1986; 15: 231-53.
30. Lee S J, Lenton E A, Sexton L, Cooke I D. The effect of age on the cyclical patterns of plasma LH, FSH, oestradiol and progesterone in women with regular cycles. Hum Reprod 1988; 3: 851-5.
31. Montz F J, Wolff A J, Gambone J C G. Gonadal protection and fecundity rates in Cyclophosphamide treated rats. Cancer Res 1991; 51: 2124-6.
32. Ataya K M, McKanna J A, Weintraub A M, Clark M R, LeMarie W J. Luteinizing hormone releasing hormone agonist for the prevention of chemotherapy induced ovarian follicular loss in rats. Cancer Res 1985; 45: 3651-6.
33. Llewellyn-Jones D, ed. The menstrual cycle and menstruation. In: Fundamentals of obstetrics and gynaecology, 4th edn, chapter 5. London: Faber and Faber, 1986; 50-60.
34. Miller R M, Frank R A. Zoladex (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy. Br J Obstet Gynaecol 1992; 99: 37-41.
35. Miyagawa S, Shirai T, Shimamoto I, Ichijo M, Ueki H. Worsening of systemic lupus erythematosus-associated thrombocytopenia after administration of gonadotrophin-releasing hormone analog. Arthritis Rheum 1994; 37: 1708-9.
36. Catania A, Mangone I, Motta P, Zanussi C. Administration of gonadotrophin-releasing analog as adjuctive therapy in women with systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1186-8.
37. Chris P, Goa K L. Goserelin: a review of its pharmacodynamic and pharmacokinetic properties and clinical use in sex hormone-related conditions. Drugs 1991; 2: 254-88.
38. Baber R, Abdalla H, Studd J. The premature menopause. In: Studd J, ed. Progress in obstetrics and gynaecology, Vol 9, chapter 13. London: Churchill Livingstone, 1991; 209-23.
39. Hopkinson N D, Doherty M, Powell R J. The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989-1990. Br J Rheumatol 1993; 32: 110-5.